Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Pharm ; 382(1-2): 98-103, 2009 Dec 01.
Article in English | MEDLINE | ID: mdl-19699285

ABSTRACT

Latex, a polyisoprene (PI) hydrophobic elastomer, was evaluated in vitro and in vivo as a matrix for intravaginal steroid hormone delivery. Matrices containing hormone were prepared by swelling latex in chloroform that contained soluble progesterone (P4). In vitro studies demonstrate that P4 release from PI follows a zero order model during at least 100 h and depends on initial load up to 10 mg cm(-2). The release of P4 from a PI matrix was found to be two times faster than from a polydimethylsiloxane (PDMS) matrix. FT-IR and X-ray powder diffraction analysis of P4 polymorphs show that when nucleated in PDMS, the hormone crystallizes only in alpha-form while in latex, crystallizes as a mixture of alpha- and beta-form. In vivo studies show that devices with a PI matrix containing 0.5 g of P4 are effective to reach plasma levels above 1 ng ml(-1) that are needed to synchronize estrous in cattle. Altogether, the results show that PI, a vulcanized polymer with a carbon-carbon backbone, can be used as a new matrix for the intravaginal administration of progesterone with improved release profile than silicone and that the matrix can influence the crystalline state of the hormone.


Subject(s)
Drug Carriers , Fertility Agents, Female/administration & dosage , Latex/chemistry , Progesterone/administration & dosage , Administration, Intravaginal , Animals , Cattle , Chemistry, Pharmaceutical , Crystallization , Crystallography, X-Ray , Dimethylpolysiloxanes/chemistry , Drug Compounding , Estrus Synchronization/drug effects , Female , Fertility Agents, Female/blood , Fertility Agents, Female/chemistry , Fertility Agents, Female/pharmacokinetics , Ovariectomy , Powder Diffraction , Progesterone/blood , Progesterone/chemistry , Progesterone/pharmacokinetics , Solubility , Spectroscopy, Fourier Transform Infrared , Technology, Pharmaceutical/methods
2.
Acta Crystallogr Sect E Struct Rep Online ; 64(Pt 1): o292, 2007 Dec 18.
Article in English | MEDLINE | ID: mdl-21200857

ABSTRACT

THE TITLE COMPOUND (SYSTEMATIC NAME: 11-cyclo-propyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one butanol 0.3-solvate), C(15)H(14)N(4)O·0.3C(4)H(9)OH, was crystallized in a new triclinic pseudopolymorphic form, a butanol solvate, and the crystal structure determined at 150 K. The mol-ecular conformation of this new form differs from that reported previously, although the main inter-molecular hydrogen-bond pattern remains the same. N-H⋯O hydrogen bonds [N⋯O = 2.957 (3) Å] form centrosymmetric dimers and the crystal packing of this new pseudopolymorph generates infinite channels along the b axis.

3.
Int J Pharm ; 298(1): 143-52, 2005 Jul 14.
Article in English | MEDLINE | ID: mdl-15913931

ABSTRACT

Solid-state physical characterization of a pharmaceutical substance is necessary for successful development and approval of the final product. Different physical analytical techniques are available to do so: X-ray diffraction (XRD), IR, Raman, DSC, TG and NMR. Moreover, all of them detect the presence of excipients perturbing the analysis of the pure substance in low doses. In order to study polymorphism and pseudo polymorphism of drug, this paper introduces possible applications of pure nuclear quadrupole resonance, as a non-destructive technique in qualitative and quantitative approaches. Chlorpropamide and diclofenac sodium were used as examples. Unlike the mentioned techniques, the nuclear quadrupole resonance (NQR) signal of pharmaceutical compounds is not perturbed by the presence of solid excipient or other substances unless they possess resonance frequencies in the same frequency range of the compound studied.


Subject(s)
Chlorpropamide/chemistry , Crystallization , Diclofenac/chemistry , Magnetic Resonance Spectroscopy , X-Ray Diffraction
SELECTION OF CITATIONS
SEARCH DETAIL
...